STATEMENT ON TRANSLATIONAL RELEVANCE
Bosutinib is a low molecular weight, orally active, competitive inhibitor of the Src and Abl tyrosine kinases. Overexpression of Src signaling pathways has been observed in malignant tumors, and in preclinical studies, bosutinib has shown antitumor activity in solid tumors including pancreas, breast, prostate, and melanoma. This first-in-human phase I trial of bosutinib in patients with advanced solid tumor malignancies demonstrated a manageable safety profile, with primarily gastrointestinal adverse events reported. The dose-proportional pharmacokinetic profile of bosutinib supported a once-daily dosing regimen, and the recommended phase II dose was determined to be 400mg/day. While 1 patient each reported complete and partial responses, and 8 other patients reported stable disease for >22 weeks, the study did not meet predetermined primary efficacy endpoints of progression-free survival and overall survival. This preliminary data suggests that Src inhibitors may need to be used in combination with other agents for the treatment of solid tumors.
Research. 
INTRODUCTION
The Src nonreceptor tyrosine kinase is one of the first oncogenes to be implicated in the causation of cancer (1) . The Src protein, a member of the Src family kinases, is a multi-domain, membrane-associated protein that functions as a critical switch in signaling cascades through the PI3 kinase, MAP kinase, and STAT pathways.
Although there is a direct role for Src in cell proliferation (2) , there is stronger evidence that Src affects cell adhesion, invasion, motility, and epithelial-mesenchymal transition in cells during the later stages of cancer progression (3) . While mutations in Src are uncommon in solid tumor malignancies, overexpression and activation of Src is common in colorectal, breast, pancreas, and lung cancer and melanoma (4, 5) .
Bosutinib (SKI-606), a 4-anilino-3-quinolinecarbonitrile, is a potent ATPcompetitive inhibitor of Src (half-maximal inhibitory concentration [IC 50 ]=3.8 nM in enzyme assays, 400 nM in lysate assays) and Abl (IC 50 =1 nM in enzyme assays, 85 nM in lysate assays) kinases (6, 7) . In addition to inhibiting Src family kinases, bosutinib also inhibits EGFR (including L858R and L861Q), EphB2, and members of the Sterile 20, Tec, and c-Kit kinase families in vitro (7) . Bosutinib inhibits solid tumors such as pancreas (8) , breast (9, 10) , prostate (9) , and melanoma (11) in preclinical models. It is also being developed for the treatment of chronic myelogenous leukemia (CML) via Abl inhibition (12) (13) (14) (15) 15) , as most agents in this class inhibit both Src and Abl. In the current study, we report the first human study of bosutinib in solid tumor malignancies and explore its activity in expanded cohorts of patients with colorectal, pancreas, and nonsmall cell lung cancer (NSCLC).
PATIENTS AND METHODS

Study Design
This phase I, prospective clinical trial was conducted in 2 parts. In part 1 (dose escalation), the maximum tolerated dose (MTD), safety profile, and a recommended phase II dose (RP2D) were determined in patients with advanced solid tumors. A standard 3+3 study design was utilized. If a dose-limiting toxicity (DLT) was observed in 1 patient during Cycle 1 (oral administration of bosutinib on Day 1 and Days 3 through 21 for a total cycle length of 21 days), the cohort was expanded to a total of 6 evaluable patients. Dose escalation continued only if no other DLTs occurred in the expanded cohort. If 2 or more of 6 patients had a DLT, the MTD was exceeded and additional patients were accrued at a lower dose to confirm the MTD, defined as the highest dose at which no more than 1 DLT occurred in the first 6 evaluable patients. In part 2 (dose expansion phase), approximately 30 evaluable patients each with refractory colorectal cancer, pancreas cancer, or NSCLC were treated at the RP2D.
Patients
Patients with advanced histologically or cytologically confirmed solid tumor malignancies were eligible for this study. Patients had to be at least 18 years of age and have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to1 or Karnofsky performance status of at last 80 (amendment 5), measurable disease as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0) (16) , and adequate organ function. In part 2, patients had had previous treatments as described in the Data Supplement (online only).
Research. Patients were excluded if they could not swallow the bosutinib capsules or had impaired lung, liver, or CNS function; a major cardiac condition; or left ventricular ejection fraction ≤50%. After the first 25 patients in part 1 were treated with bosutinib, patients who were on warfarin were excluded due to elevated coagulation tests (increased international normalized ratio) for 2 of 3 patients on warfarin. In part 2 of the study, patients on warfarin were required to reduce their warfarin dose by 50%, initially, and further dose modifications were made as required after the first 2 weeks of bosutinib treatment.
The study protocol was approved by the institutional review boards at participating institutions and all patients gave written informed consent. The study was conducted according to good clinical practice and the Declaration of Helsinki and its amendments. The trial was registered at www.clinicaltrials.gov as #NCT00195260.
Drug Administration
In the dose escalation part of the study, patients received a single daily dose of bosutinib with food. The initial dose, 50 mg, was 10% of the dose in rats that was severely toxic to 10% of the animals, 42 mg/m 2 (17). Other planned doses were 100, 200, 300, 400, 500, 600, 800, and 1000 mg. A DLT was defined as any of these possibly bosutinib-related events that occurred in the first cycle of the trial: (1) any grade 3 or 4 (National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0) non-hematologic toxicity, (2) grade 4 neutropenia with a duration of at least 7 days or with fever of at least 38. previously described (11) . The slides were scored by 2 independent pathologists in a blinded fashion.
Statistical Analysis
The sample size for the dose escalation phase of the study was determined by clinical considerations. For the dose expansion part of the study, the sample size (n=30) was calculated based on a 1-arm parametric design for PFS or OS. Approximately 108 patients were to be enrolled at the MTD (36 per cohort) to attain 90 evaluable patients (30 per cohort), assuming an unevaluable rate of 15%. For the purposes of this study, the promising ranges (and power to detect a difference) were median PFS ≥12 weeks (97%) for colorectal cancer (CRC), median PFS ≥13 weeks (81%) for NSCLC, and median OS ≥24 weeks (99%) for pancreas cancer, versus historical ranges of median PFS ≤6 weeks for CRC, median PFS ≤8 weeks for NSCLC, and median OS ≤10 weeks for pancreas cancer.
RESULTS
Patient Characteristics
A total of 151 patients were enrolled in the dose escalation (part 1, n=51) and dose expansion (part 2, n=100) portions of the study. The baseline characteristics of the study patients are shown in Table 1 .
Dose Escalation
No DLTs were observed in cohort 1 (50 mg/day, n=4) or cohort 2 (100 mg/day, n=4). In cohort 3 (200 mg/day), 1 of 6 patients had a DLT of grade 3 abdominal pain. In the next cohort (300 mg/day), 1 of 7 patients had a DLT of grade 3 rash. At the 400-mg dose level (n=7), no DLTs were observed (cohort was expanded due to INR increases observed in patients on warfarin). At 500 mg/day, 1 of 7 patients had grade 3 diarrhea.
At the 600-mg dose level, 3 of 10 patients had DLTs; grade 3 rash (1) and grade 3 diarrhea (2). Thus, the MTD was exceeded and 6 additional patients were treated with bosutinib at 500 mg/day, the MTD lead-in dose. No DLTs were reported but grade 2 or 3 gastrointestinal toxicity occurred in 4 of 6 patients. Therefore, the 400-mg/day dose was chosen as the RP2D.
Safety and Toxicity Profile
All 151 patients enrolled received at least 1 dose of bosutinib and, by study definition, were evaluable for safety. The median number of doses of bosutinib was 36 (range, 1-616) and the median duration of treatment was 5.6 weeks (range, 0.1-95 weeks). The mean relative dose intensity (total actual doses divided by total assigned doses) was 0.92. Patients discontinued bosutinib treatment because of disease progression (65% patients), adverse events (14%), symptomatic deterioration (9%), patient or investigator request (8%), death (3%), and other (1%).
The most common bosutinib-related adverse events were nausea (60% patients) diarrhea (47%), vomiting (40%), fatigue (38%), and anorexia (36%, 
common grade 3 or 4 related adverse events were diarrhea (9% patients), alanine aminotransferase (ALT) elevation (4%), and fatigue (4%).
No grade 4 diarrhea occurred; of the patients who had bosutinib-related diarrhea, 82% and 18% had grade 1-2 and grade 3 severity, respectively, as their maximum toxicity. Six patients had dose reductions and 1 discontinued bosutinib treatment because of diarrhea. Four patients required hospitalization with 3 requiring intravenous infusion for more than 24 hours. Ophthalmologic evaluations were performed at baseline (149 patients) and at the final visit (31) . No ophthalmologic adverse events of grade 2 or higher were reported.
Bosutinib dose reductions due to adverse events were required for 28 (19%) patients of the total study population; 18 (18%) patients who received bosutinib 400 mg, the RP2D, required dose reductions. Diarrhea (6 patients), fatigue and increased ALT and aspartate aminotransferase (AST) levels (5 patients each), nausea (4), and increased blood creatinine levels (3) were the most common reasons patients had dose reductions. Adverse events led to the discontinuation of bosutinib for 29 (19%) patients in the study; and in 18 (18%) patients in the dose expansion cohort. Increased ALT levels and acute renal failure (3 patients each) were the most common reasons patients discontinued treatment.
Pharmacokinetic Evaluations
Plasma samples were available from 98 patients who received oral bosutinib doses ranging from 50 mg to 600 mg. A summary of bosutinib pharmacokinetic parameters after patients received a single dose on study Day 1 and once daily multiple doses through study Day 15 are presented in Table 3 . After treatment with single and multiple doses of bosutinib, absorption was slow with a median time to peak concentration (T max ) of 4 to 6 hours. Mean peak concentration (C max ) and area under the concentration-time curve (AUC) of bosutinib after a single dose or once daily doses increased with increasing dose of bosutinib. Multiple-dose exposure was 1.9-to 3.0-fold greater than single-dose exposure for 50-mg to 600-mg doses.
After a single dose of bosutinib on Day 1, the mean apparent volume of distribution (V z /F) was large and ranged from 6000 to 11100 L, the mean apparent oral clearance (CL/F) ranged from 207 to 721 L/h, and the mean half-life (t 1/2 ) ranged from 13 to 22 hours.
Pharmacodynamics
Levels of phosphorylated Src and total Src were measured in platelet lysates from patients treated with different doses of bosutinib. Median and mean values indicated no consistent inhibition of Src kinase activity versus time (Fig A1, online only) .
However, at steady state on study Day 15, when lysates were prepared at 6 hours after bosutinib administration, close to the median t max of 4 to 5 hours, there was a trend toward inhibition of phosphorylation of Src (Fig A1B, online only) . No definite conclusion can be drawn from this analysis because of the variable number of lysates that were available for assay (n=2-14) and the variability in the assay results (coefficient of variation: 4%-156%). were measured by immunohistochemistry. No consistent decrease in levels of these proteins after bosutinib treatment was observed (Table A1 , online only).
Efficacy
In part 1 of the study, a patient with breast cancer (500-mg dose reduced to 400 mg) had a partial response lasting 18 weeks. Stable disease occurred in 54% of the evaluable patients in part 1 (Table A2 , online only). Three patients (breast, NSCLC, and pancreas cancer) had stable disease 23 to 101 weeks.
In part 2 of the study, 1 patient with recurrent pancreatic cancer in a paraaortic lymph node had an unconfirmed complete response and remained in remission for more than 42 months since discontinuing treatment. Stable disease occurred in 29% of evaluable patients (Table 4) . Five patients (2 CRC, 3 NSCLC) had stable disease for 22 to 50 weeks. The maximum percentage reduction in target tumor sizes from baseline is presented in Figure 1 . Median PFS was 6.0 weeks for colorectal and pancreas cancer patients and 5.7 weeks for NSCLC patients (Figure 2A ). Median OS was 34.0, 27.7, and 14.7 weeks for NSCLC, colorectal, and pancreas cancer patients, respectively ( Figure   2B ).
DISCUSSION
Bosutinib is a potent, orally bioavailable small-molecule Src/Abl kinase inhibitor (6, 7) . We evaluated the safety, pharmacokinetics, and preliminary single-agent efficacy of this drug in patients with advanced solid tumor malignancies in a two-part phase I trial. Although the MTD was 500 mg/day, grade 2 gastrointestinal toxicity was observed in approximately 30% of patients; thus, for long term tolerability, the RP2D was 400
Research. The most common bosutinib-related adverse events in this study were nausea, diarrhea, vomiting, fatigue, and anorexia. Bosutinib also is being evaluated in CML and similar toxicities have been reported for patients resistant or intolerant to imatinib (13) (14) (15) . Transaminase elevations and fatigue were the main reasons for dose reductions in patients with advanced solid tumor malignancies who were treated at the RP2D.
Since Src activation is more clearly associated with tumor invasiveness than cell proliferation, we expected Src inhibition to result in tumor stabilization rather than shrinkage. A partial response was observed in a patient with breast cancer in part 1 of the trial and an unconfirmed complete response was observed in a patient with pancreas cancer in part 2. Three and 5 patients in parts 1 and part 2, respectively, had stable disease for 22 to 101 weeks. However, in part 2 of the trial, the primary efficacy endpoints for single-agent activity were not met.
Two other Src/Abl kinase inhibitors are being studied as possible treatments for patients with advanced solid tumors. The 5,7 substituted anilinoquinazoline Src inhibitor saracatinib (AZD0530; Src IC 50 =2.7 nM) (19) had an RP2D of 175 mg/day with leucopenia, renal failure and septic shock, and asthenia as DLTs (20). Anemia, thrombocytopenia, gastrointestinal toxicities, and asthenia were the most common drugrelated adverse events. Of the 81 patients in the study, none had a complete or partial response but 16% were on study for at least 12 weeks. Similar activity was reported in Abbreviations: C max , peak concentration; t max , time to peak concentration; t 1/2 , terminal phase elimination half-life; AUC, area under the concentration-time curve; CL/F, apparent oral dose clearance (dose/AUC); V Z /F, apparent volume of distribution; AUC SS , area under the concentration-time curve at steady state; R, mean accumulation ratio (AUC ss /AUC 0-24 h ).
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